share_log

BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024

BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024

BriaCell 在 AACR 2024 上重點介紹抗體偶聯物耐藥和中樞神經系統轉移性乳腺癌的數據
Benzinga ·  04/09 20:49
  • PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT pivotal Phase 3 formulation is twice that of controls in similar studies
  • PFS results reinforced by larger number of prior treatments in Bria-IMT population than in comparable studies
  • Bria-IMT PFS compares favorably to their most recent treatment PFS in 48% of patients
  • Clinical benefit rate of 56% in evaluable patients
  • 71% intracranial objective response rate (iORR) in heavily pretreated patients
  • Findings support clinical efficacy of Bria-IMT and highlight its significant potential in managing CNS metastatic disease in advanced breast cancer
    • Additional preclinical anti-cancer data of Bria-OTS+ and Bria-PROS+ will be presented tomorrow 9:00 AM - 12:30 PM PST; Abstract Presentation Number: 6753
  • 在接受Bria-imt關鍵3期製劑的2期ADC耐藥患者中，PFS爲4.2個月，是類似研究中對照組的兩倍
  • 與同類研究相比，Bria-imt人群先前接受的治療數量更多進一步證實了PFS結果
  • 在48％的患者中，Bria-imt PFS與他們最近的治療PFS相比表現良好
  • 可評估患者的臨床獲益率爲 56%
  • 大量預治療患者的顱內客觀反應率 (IorR) 爲 71%
  • 研究結果支持bria-imt的臨床療效，並凸顯了其在管理晚期乳腺癌中樞神經系統轉移疾病方面的巨大潛力
    • Bria-OTS+ 和 Bria-Pros+ 的其他臨床前抗癌數據將於太平洋標準時間明天上午 9:00 至下午 12:30 公佈；摘要演示編號：6753

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論